Australia's most trusted
source of pharma news
Monday, 08 July 2024
Posted 4 July 2024 AM
After securing a recommendation at this year's March PBAC meeting six drugs have already stalled in the PBS listing process with the applications for reimbursement marked 'inactive'.
Drug applications are considered inactive when a company has not advised whether they intend to proceed or not within 60 days of receiving the ratified PBAC minutes and often flags issues on conditions of the recommendation, such as pricing.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.